Related Experiment Video
Updated: Dec 10, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
PP2A and tumor radiotherapy
1The First Medical Center of Chinese PLA General Hospital, Department of Radiation Oncology, Beijing, P. R. China.
Abstract:
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that serves as a key regulator of cellular physiology in the context of apoptosis, mitosis, and DNA damage responses. Canonically, PP2A functions as a tumor suppressor gene. However, recent evidence suggests that inhibiting PP2A activity in tumor cells may represent a viable approach to enhancing tumor sensitivity to chemoradiotherapy as such inhibition can cause cells to enter a disordered mitotic state that renders them more susceptible to cell death. Indeed, there is evidence that inhibiting PP2A can slow tumor growth following radiotherapy in a range of cancer types including ovarian cancer, liver cancer, malignant glioma, pancreatic cancer, and nasopharyngeal carcinoma. In the present review, we discuss current understanding of the role of PP2A in tumor radiotherapy and the potential mechanisms whereby it may influence this process.
Insights
Inhibiting Protein Phosphatase 2A (PP2A) in cancer cells can enhance their sensitivity to chemoradiotherapy. This approach disrupts mitosis, making tumor cells more susceptible to cell death and slowing cancer growth.
Area of Science:
- Molecular Biology
- Oncology
- Cellular Physiology
Background:
- Protein Phosphatase 2A (PP2A) is a crucial serine/threonine phosphatase regulating apoptosis, mitosis, and DNA damage responses.
- PP2A traditionally functions as a tumor suppressor, but its inhibition is emerging as a therapeutic strategy.
Purpose of the Study:
- To review the current understanding of PP2A's role in tumor radiotherapy.
- To explore potential mechanisms by which PP2A inhibition influences radiotherapy efficacy.
Main Methods:
- Literature review of studies on PP2A, cancer, and radiotherapy.
- Analysis of cellular and molecular mechanisms linking PP2A activity to treatment response.
Main Results:
- PP2A inhibition can induce mitotic catastrophe in tumor cells, increasing radiosensitivity.
- Evidence suggests PP2A inhibition slows tumor growth across various cancer types post-radiotherapy.
Conclusions:
- Targeting PP2A activity represents a promising strategy to enhance chemoradiotherapy outcomes.
- Further research into PP2A's mechanisms in cancer treatment is warranted.
More Related Videos
05:18Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
06:42Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
Published on: May 9, 2025
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy